Evidence map›Paper›PMID 35286144›Full record

ArticleAnnals of internal medicine2022

Comparison of SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction and BinaxNOW Rapid Antigen Tests at a Community Site During an Omicron Surge : A Cross-Sectional Study.

John Schrom, Carina Marquez, Genay Pilarowski, Chung-Yu Wang, Anthea Mitchell, Robert Puccinelli, Doug Black, Susana Rojas, Salustiano Ribeiro, Valerie Tulier-Laiwa and 11 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 6 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 6 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Validating Combination Throat-Nasal Swab Specimens for COVID-19 Tests Would Improve Early Detection, Especially for the Most Vulnerable.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

John SchromUniversity of California, San Francisco, San Francisco, California (J.S., C.M., D.B., G.C., V.J., D.H.).ORCID 0000-0002-3871-4311
Carina MarquezUniversity of California, San Francisco, San Francisco, California (J.S., C.M., D.B., G.C., V.J., D.H.).
Genay PilarowskiUnidos en Salud, San Francisco, California (G.P., S.Ribeiro, J.M., J.P., D.J., D.M.).ORCID 0000-0001-8270-8771
Chung-Yu WangChan Zuckerberg Biohub, San Francisco, California (C.W., A.M., J.D.).
Anthea MitchellChan Zuckerberg Biohub, San Francisco, California (C.W., A.M., J.D.).
Robert PuccinelliUniversity of California, Berkeley, Berkeley, California (R.P., M.P.).ORCID 0000-0002-8614-8326
Doug BlackUniversity of California, San Francisco, San Francisco, California (J.S., C.M., D.B., G.C., V.J., D.H.).
Susana RojasUnidos en Salud and San Francisco Latino Task Force for COVID-19, San Francisco, California (Susana Rojas, V.T., Susy Rojas).
Salustiano RibeiroUnidos en Salud, San Francisco, California (G.P., S.Ribeiro, J.M., J.P., D.J., D.M.).ORCID 0000-0002-7482-2336
Valerie Tulier-LaiwaUnidos en Salud and San Francisco Latino Task Force for COVID-19, San Francisco, California (Susana Rojas, V.T., Susy Rojas).
Jacqueline MartinezUnidos en Salud, San Francisco, California (G.P., S.Ribeiro, J.M., J.P., D.J., D.M.).
Joselin PayanUnidos en Salud, San Francisco, California (G.P., S.Ribeiro, J.M., J.P., D.J., D.M.).
Susy RojasUnidos en Salud and San Francisco Latino Task Force for COVID-19, San Francisco, California (Susana Rojas, V.T., Susy Rojas).
Diane JonesUnidos en Salud, San Francisco, California (G.P., S.Ribeiro, J.M., J.P., D.J., D.M.).ORCID 0000-0002-0375-5500
Daniel MartinezUnidos en Salud, San Francisco, California (G.P., S.Ribeiro, J.M., J.P., D.J., D.M.).
Robert NakamuraCalifornia Department of Public Health, Richmond, California (R.N.).
Gabriel ChamieUniversity of California, San Francisco, San Francisco, California (J.S., C.M., D.B., G.C., V.J., D.H.).ORCID 0000-0002-5860-8081
Vivek JainUniversity of California, San Francisco, San Francisco, California (J.S., C.M., D.B., G.C., V.J., D.H.).
Maya PetersenUniversity of California, Berkeley, Berkeley, California (R.P., M.P.).
Joe DeRisiChan Zuckerberg Biohub, San Francisco, California (C.W., A.M., J.D.).ORCID 0000-0002-4611-9205
Diane HavlirUniversity of California, San Francisco, San Francisco, California (J.S., C.M., D.B., G.C., V.J., D.H.).ORCID 0000-0003-0761-3136
United in Health · USUniversity of California, San Francisco · USChan Zuckerberg Initiative (United States) · USUniversity of California, Berkeley · USCalifornia Department of Public Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV-2 rapid antigen tests are an important public health tool.

objectiveTo evaluate field performance of the BinaxNOW rapid antigen test (Abbott) compared with reverse transcriptase polymerase chain reaction (RT-PCR) for detecting infection with the Omicron variant of SARS-CoV-2.

designCross-sectional surveillance study.

settingFree, walk-up, outdoor, urban community testing and vaccine site led by Unidos en Salud, serving a predominantly Latinx community highly impacted by COVID-19.

participantsPersons seeking COVID-19 testing in January 2022. MEASUREMENTS: Simultaneous BinaxNOW and RT-PCR from nasal, cheek, and throat swabs, including cycle threshold (Ct) measures; a lower Ct value is a surrogate for higher amounts of virus.

resultsAmong 731 persons tested with nasal swabs, there were 296 (40.5%) positive results on RT-PCR; 98.9% were the Omicron variant. BinaxNOW detected 95.2% (95% CI, 91% to 98%) of persons who tested positive on RT-PCR with a Ct value below 30, 82.1% (CI, 77% to 87%) of those who tested positive on RT-PCR with a Ct value below 35, and 65.2% (CI, 60% to 71%) of all who were positive on RT-PCR. Among 75 persons with simultaneous nasal and cheek swabs, BinaxNOW using a cheek swab failed to detect 91% (20 of 22) of specimens that were positive on BinaxNOW with a nasal swab. Among persons with simultaneous nasal and throat swabs who were positive on RT-PCR with a Ct value below 30, 42 of 49 (85.7%) were detected by nasal BinaxNOW, 23 of 49 (46.9%) by throat BinaxNOW, and 44 of 49 (89.8%) by either. LIMITATION: Participants were a cross-sectional sample from a community-based sentinel surveillance site, precluding study of viral or symptom dynamics.

conclusionBinaxNOW detected persons with high SARS-CoV-2 levels during the Omicron surge, enabling rapid responses to positive test results. Cheek or throat swabs should not replace nasal swabs. As currently recommended, high-risk persons with an initial negative BinaxNOW result should have repeated testing. PRIMARY FUNDING SOURCE: University of California, San Francisco.

Indexed as

COVID-19SARS-CoV-2Antigens, ViralCOVID-19 TestingCross-Sectional StudiesHumansReverse Transcriptase Polymerase Chain ReactionSensitivity and SpecificityAntigens, Viral

Identifiers

PMID35286144
PMCPMC8943844
OpenAlexW4220786037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.